

MAVIRET FOR THE TREATMENT OF HEPATITIS C

TALK TO YOUR DOCTOR ABOUT MAVIRET

MAVIRET® is a prescription medicine used to treat adults and adolescents 12 years and older with the hepatitis C (hep C) virus.

MAVIRET belongs to a group of medicines called direct-acting antiviral agents (DAAs). MAVIRET is a combination of two medicines that work together to stop the hep C virus from multiplying and infecting new cells. This allows the infection to be eliminated from the body.

Based on clinical trials, 98% of people who take MAVIRET as directed and who are new to treatment can expect to be cured* of their hep C, meaning that the hep C virus has been cleared from the body.

*Cure means the hep C virus is not found in the blood 3 months after treatment ends.

QUESTIONS ABOUT MAVIRET TO CONSIDER ASKING YOUR DOCTOR

How effective will MAVIRET be for me?

How long would I have to take MAVIRET?

What side effects might I expect from MAVIRET?

If I have other illnesses, is MAVIRET right for me?

If MAVIRET is right for me, which pharmacy will I pick it up from? You can only get MAVIRET from certain pharmacies. (Find pharmacy locations at www.maviret.co.nz)

Be sure to tell your doctor about all the medicines you take, including prescription and over-the counter medicines, vitamins and herbal supplements. It is also important to tell your doctor if you are hepatitis B positive.

Notes:

References: 1. MAVIRET Consumer Medicine Information. 2. MAVIRET Data Sheet. 3. Puoti M et al. Journal of Hepatology 2018;69(2):293-300.

MAVIRET is a fully funded medicine with an alternative arrangement on how it is available to you. Your prescriber will explain this to you.

IMPORTANT INFORMATION ABOUT MAVIRET®

MAVIRET® is a prescription medicine containing a combination tablet of 100 mg of glecaprevir and 40 mg of pibrentasvir. It is used to treat adults and adolescents 12 years and older with acute or chronic (long-lasting) hepatitis C virus (HCV). This medicine belongs to a group of medicines called direct-acting antiviral agents. Ask your doctor if you have any questions about why MAVIRET® has been prescribed for you.

MAVIRET has risks and benefits. You must not take MAVIRET® if you are allergic to any of the medicines contained in MAVIRET®, or to any of the inactive ingredients. Do not take it if you have severe liver disease; if you are taking atazanavir or rifampicin containing products. Before you use MAVIRET®, tell your doctor if you have or have had liver problems other than hepatitis C infection, HIV infection, hepatitis B infection, or a liver or kidney transplant. Tell your doctor or pharmacist if you have or have had diabetes. Tell your doctor or pharmacist if you are pregnant, trying to become pregnant or if you are breastfeeding or are planning to breastfeed. Do not give MAVIRET® to a child under the age of 12 years. Some medicines and MAVIRET® may interfere with each other, so tell your doctor if you are taking medicines containing any of the following: atorvastatin, simvastatin, pravastatin, rosuvastatin, lovastatin, carbamazepine, ciclosporin, darunavir, lopinavir, ritonavir, efavirenz, dabigatran, digoxin, ethinyloestradiol, fluindione, warfarin or other vitamin K antagonists, St John's wort. Some of the more common side effects of MAVIRET® include feeling very tired, headache and nausea. Other side effects may occur in some people. Tell your doctor, nurse or pharmacist if you notice anything that is making you feel unwell.

If you have any questions about using MAVIRET, including its risks and benefits, how much to use, how and when to use it, ask your healthcare professional and refer to the Consumer Medicine Information (CMI) available from the Medsafe website www.medsafe.govt.nz or free phone 0800 900 030. Ask your doctor if MAVIRET is right for you. Normal doctor's charges apply. Always use strictly as directed. If symptoms continue, or you have side effects, see your doctor, pharmacist or healthcare professional.

©2026 AbbVie. All rights reserved. AbbVie® is a registered trademark of AbbVie Inc. MAVIRET® is a registered trademark of AbbVie Manufacturing Management Unlimited Company. AbbVie Limited, Wellington 6011, New Zealand. TAPS BG5970. NZ-MAVI-230031. MAV0297. August 2026.